iRadimed (IRMD) Stock Price, News & Analysis

Company Overview

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Key Stats

• Today's Range: $55.11 to $58.00
• 50-Day Range: $51.09 to $61.83
• 52-Week Range: $42.34 to $63.29
• Volume: 30,681 shs
• Average Volume: 53,572 shs
• Market Capitalization: $716.39 million
• P/E Ratio: 36.34
• Dividend Yield: 1.21%
• Price Target: $72.00
• Consensus Rating: Buy

iRadimed Stock Analysis - MarketRank™

iRadimed scored higher than 98% of companies evaluated by MarketBeat, and ranked 33rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

iRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

iRadimed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 20.48%

Earnings Growth

Earnings for iRadimed are expected to grow by 20.48% in the coming year, from $1.66 to $2.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iRadimed is 36.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of iRadimed is 36.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.41.

Price to Book Value per Share Ratio

iRadimed has a P/B Ratio of 8.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.88% of the float of iRadimed has been sold short.

Short Interest Ratio / Days to Cover

iRadimed has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in iRadimed has recently decreased by 3.02%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

iRadimed pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

iRadimed has only been increasing its dividend for 1 years.

Dividend Coverage

The dividend payout ratio of iRadimed is 43.87%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, iRadimed will have a dividend payout ratio of 34.00% next year. This indicates that iRadimed will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

2.88% of the float of iRadimed has been sold short.

Short Interest Ratio / Days to Cover

iRadimed has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in iRadimed has recently decreased by 3.02%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.26

News Sentiment

iRadimed has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for iRadimed this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iRadimed insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.80% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRMD Stock Analysis - Frequently Asked Questions

How have IRMD shares performed this year?

iRadimed's stock was trading at $55.00 at the start of the year. Since then, IRMD shares have increased by 2.4% and is now trading at $56.32.

How were iRadimed's earnings last quarter?

iRadimed Corporation (NASDAQ:IRMD) posted its quarterly earnings results on Thursday, February, 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by $0.05. The medical equipment provider had revenue of $19.39 million for the quarter, compared to analyst estimates of $19.09 million. iRadimed had a trailing twelve-month return on equity of 23.28% and a net margin of 26.33%.
Read the conference call transcript.

Who are iRadimed's major shareholders?

iRadimed's top institutional shareholders include Copeland Capital Management LLC (3.60%), Oak Ridge Investments LLC (0.31%), Johnson Investment Counsel Inc. (0.20%) and KLP Kapitalforvaltning AS (0.09%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn.
View institutional ownership trends.

How do I buy shares of iRadimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iRadimed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/13/2025
• Record date for 5/30 Dividend: 5/20/2025
• Ex-Dividend for 5/30 Dividend: 5/20/2025
• Dividend Payable: 5/30/2025
• Today: 7/27/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRMD
• CIK: 1325618
• Web: www.iradimed.com
• Phone: (407) 677-8022
• Fax: 407-677-5037
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iRadimed: $72.00
• High Price Target: $72.00
• Low Price Target: $72.00
• Potential Upside/Downside: +27.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.55
• Trailing P/E Ratio: 36.34
• Forward P/E Ratio: 33.93
• P/E Growth: N/A
• Net Income: $19.23 million
• Net Margins: 26.33%
• Pretax Margin: 33.23%
• Return on Equity: 23.28%
• Return on Assets: 20.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.87
• Quick Ratio: 7.62

Sales & Book Value

• Annual Sales: $73.24 million
• Price / Sales: 9.78
• Cash Flow: $1.58 per share
• Price / Cash Flow: 35.60
• Book Value: $6.85 per share
• Price / Book: 8.22

Miscellaneous

• Outstanding Shares: 12,720,000
• Free Float: 8,036,000
• Market Cap: $716.39 million
• Optionable: Optionable
• Beta: 0.91